Quick Answer
Janux Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $52.33 million for the year ending 2025.
- Janux Therapeutics, Inc. showed a decrease of -87.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $251.63 million | Q3 2021: $39.39 million | Q1 2022: $55.13 million | Q2 2022: $58.40 million | Q3 2022: $64.75 million | Q1 2023: $30.36 million | Q2 2023: $33.70 million | Q3 2023: $17.15 million | Q1 2024: $212.80 million | Q2 2024: $14.66 million | Q3 2024: $26.75 million | Q1 2025: $73.74 million | Q2 2025: $52.45 million | Q3 2025: $48.39 million.
- Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 569.8%.
- Historical annual values: Fiscal year 2025: $52.33 million | Fiscal year 2024: $430.61 million | Fiscal year 2023: $19.21 million | Fiscal year 2022: $51.43 million | Fiscal year 2021: $35.58 million | Fiscal year 2020: $7.81 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: